GammaCan International Inc., Appoints Dr. Pearl Grimes, Founder & Director of the Vitiligo and Pigmentation Institute of Souther
September 21 2006 - 6:30AM
Business Wire
GammaCan International, Inc. (OTC BB: GCAN) today announced the
appointment of Dr. Pearl Grimes, Founder & Director of the
Vitiligo and Pigmentation Institute of Southern California and
Clinical Professor of Dermatology at the University of California,
Los Angeles, to the Company's Scientific Advisory Board. Dr. Grimes
is nationally and internationally recognized for her work on
pigmentary disorders. She lectures worldwide on pigmentary
disorders including vitiligo, Melasma, and post-inflammatory
hyperpigmentation to name a few. "We view the appointment of Dr
Grimes to our SAB as critical to GammaCan's mission reaching out to
the large population affected by Vitiligo whom Dr. Grimes has made
her life's mission to help. Moreover, we see substantial synergies
in our mutual interest involving the study of Vitiligo and thus in
bringing VitiGam into the clinic and later on to the market,"
stated Patrick Schnegelsberg, CEO. Dr. Grimes is the past Assistant
Editor of the Journal of the American Academy of Dermatology, and
has served on the Editorial Board of the Journal of Clinical
Dermatology, Practical Dermatology, and Skin & Allergy News.
Dr. Grimes is presently a contributing editor to Cosmetic
Dermatology. As founder of The Vitiligo and Pigmentation Institute
of Southern California and its ongoing research program, Dr.
Grimes' mission is to provide cutting edge therapies to patients
suffering from vitiligo and other pigmentary disorders. She has
authored over 100 publications and abstracts and is a member of:
The American Academy of Dermatology, the American Society of
Dermatological Surgery, the American Dermatological Association,
Society of Investigative Dermatology, Dermatology Foundation, and
International Pigment Cell Society. Dr. Grimes is a graduate of
Washington University in St. Louis, Missouri and completed her
dermatology residency at Howard University Hospital in Washington,
D.C. About VitiGam: VitiGam is GammaCan's second generation
intravenous IgG-based product and a first-in-class anti-cancer
immunotherapy. GammaCan plans on having VitiGam to enter phase I/II
testing under a US IND in the near future after it recently held a
pre-IND meeting with the FDA. VitiGam is being designed to target
metastatic melanoma patients with Stage III and IV melanoma.
VitiGam is an IgG product that is different from standard IgGs: It
is manufactured from the plasma of donors with vitiligo, a benign
autoimmune skin condition affecting up to 2% of the general
population. GammaCan scientists have shown that this "enriched"
vitiligo IgG (VitiGam) contains potent anti-melanoma activity in
both in vitro and mouse xenograft melanoma models. Thus, GammaCan
expects VitiGam to provide (1) anti-melanoma activity directed
specifically against malignant melanoma cells and (2) non-specific
anti-cancer activity - as is the case with IgG in general. About
GammaCan GammaCan is focusing on the commercialization of an
innovative anti-cancer immunotherapy to treat metastatic cancer.
GammaCan's platform is based on IgG, a safe, relatively non-toxic
human plasma-based product, currently used to treat a variety of
immune deficiencies and autoimmune diseases. IgG works by
strengthening the patient's immune system. Many experts currently
view immunotherapy as a future alternative to today's standard
chemotherapy. GammaCan is developing VitiGam, its second generation
program. VitiGam is an IgG derived from the plasma of vitiligo
donors and is being developed to treat malignant melanoma. GammaCan
owns, and has applied for US patent protection covering the use of
IgG and vitiligo-derived IgG (VitiGam). For more information about
GammaCan visit www.GammaCan.com or call the company's headquarters
in Kiryat Ono, Israel at +972 (03) 738-2616 or toll free
1-866-308-0396 (from North America). Safe Harbor Statement:
Statements in this document that are not purely historical are
forward-looking statements. Forward-looking statements in this
release include statements regarding the commercialization of an
anti-cancer immunotherapy and the Company developing the boosting
of cancer patients' immune systems with IgG into an effective
treatment. Actual outcomes and the Company's actual results could
differ materially from those in such forward-looking statements.
Factors that could cause actual results to differ materially
include risks and uncertainties such as the inability to finance
the planned development of the technology, unforeseen technical
difficulties in developing the technology, the inability to obtain
regulatory approval for human use, competitors' therapies proving
more effective, cheaper or otherwise preferable for consumers,
inability to market the product we produce, among other factors,
all of which could among other things, delay or prevent product
release or cause our company to fail. For further risk factors see
the risk factors associated with other early state medical research
and development companies filed with the SEC on Edgar.
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jul 2023 to Jul 2024